Longevity Daily
The most relevant research on longevity, biohacking, and regenerative medicine — straight from the world’s best sources. No marketing filters.
Last updated: April 10 at 02:45 PM
NPPA Gene Therapy to Encourage Greater Regeneration Following Heart Attack
Researchers here describe a novel approach to encourage greater regeneration in heart tissue following the injury and lost function incurred during a heart attack. Their work falls into the growing category of practical gene therapies in which a small amount of easily accessible
Vulnerability to Infection Resulting from the Aging of the Immune System
Researchers here review the landscape of immune aging with a particular focus on vulnerability to respiratory infections, such as influenza. As we age the immune system becomes ever less capable, the outcome of impaired manufacture of new immune cells, as well as issues that affe
Arg-1 Makes Macrophages More Inflammatory, Impairing Cartilage Regeneration with Age
Cartilage tissue exhibits a relatively poor capacity for regeneration even in youth, but this capacity for maintenance and repair diminishes with age. There are thus some gains to be made in understanding why this happens and developing means of rejuvenation, but ultimately some
Fountain Life adds APEX to premium longevity program
New membership blends full-body screening with fitness and movement testing, as Fountain Life deepens commitment to always-on preventive care. Leading health longevity brand Fountain Life is making a bigger bet that longevity should not be a once-a-year checkup, but an ongoing sy
Erectile dysfunction drugs and longevity
When it comes to PDE5 inhibitors, Longevity.Technology’s DLT Chatbot asks can you teach old drugs,new tricks? PDE5 inhibitors have long been associated with some of medicine’s most commercially successful drugs. Best known for treating erectile dysfunction and pulmonary hypertens
NADMED backs Cleveland Clinic transplant study
$30,000 award backs research that improves donor organ assessment and shows how redox biology edging closer to real-world longevity medicine. This week, Finnish biotech NADMED named Cleveland Clinic as the inaugural recipient of its $30,000 NADMED Award, backing a project led by
Merck bets on antibody startup Infinimmune for longevity edge
Deal worth up to $838 million suggests Big Pharma is looking for faster, more human-first ways to build medicines that shape healthier aging. When a pharmaceutical giant like Merck hands a 10-person biotech startup a deal worth up to $838 million, it is tempting to focus only on
Annovis traces buntanetap’s road to Alzheimer’s
A new The Scientist feature revisits the long, strange history of Annovis’ lead drug candidate as its Phase 3 Alzheimer’s trial moves forward. Phase 3 clinical-stage biotech Annovis Bio has published a historical review in The Scientist titled “Buntanetap: From Execution Poison t
Scala Biodesign lands $16m to speed protein R&D
Fresh Series A funding backs a platform designed to help drugmakers cut years of trial and error from protein-based medicine development. Scala Biodesign, a Tel Aviv-based biotech company building software for protein design, has raised $16 million in Series A financing to expand
PANoptosis in the Aging of the Heart
As the understanding of more recently discovered modes of programmed cell death are fleshed out, they receive greater attention from various groups focused on specific aspects of aging. In this review the programmed cell death mechanism is PANoptosis and the area of focus is the
High Dose Influenza Vaccine Correlates with Greater Reduction in Dementia Risk
Does the correlation between late life vaccination and reduced risk of neurodegenerative conditions such as Alzheimer's disease exist because vaccination produces benefits such as reduced chronic inflammation via trained immunity, or because people who undergo vaccination tend to
NeuroTherapia completes Phase 2a trial of NTRX-07 in Alzheimer’s
NeuroTherapia, Inc. completed a 28-day, double-masked, randomized Phase 2a trial of its oral candidate, NTRX-07, in patients with Alzheimer’s disease. The trial enrolled 48 subjects in a 1:1 randomized design across five sites in Hungary, Poland and the Czech Republic and was man
Airna doses first patient in Phase 1 trial of AIR-001 for AATD
Airna announced that the first patient has been dosed in the global Phase 1 clinical trial of AIR-001, its RNA-editing therapeutic candidate for alpha-1 antitrypsin deficiency (AATD). The open-label RepAIR1 study (NCT07431112) is an integrated single ascending and multiple dose t
Data on the Effective Long Term Treatment of Transthyretin Amyloidosis
Transthyretin is one of a small number of proteins that can misfold and aggregate to cause pathology in tissues, primarily the cardiovascular system, but other organs as well once aggregation becomes very severe. Despite being a universal mechanism that operates in all older indi
AHR Inhibition Promotes Greater Axon Regeneration in the Nervous System
The capacity for neurons to regrow the axons that connect them is relatively limited. The tissue of large nerves, largely made up of axons, does not readily regenerate; the closer to the central nervous system one comes, the less the capacity for regrowth following injury. This i
First Human Data for Rubedo Life Sciences' Senolytic Drug RLS-1496
New senolytic drugs to clear the accumulation of senescent cells in aged tissues are working their way into clinical trials at the usual slow pace for medical development, slowed even further by the poor biotech investment market of the past three years. Rubedo Life Science's fir
#386 – Aging clocks—what they measure, how they work, and their clinical and real-world relevance
" The biomarkers that capture aspects of the aging process could help us prioritize which ideas are worth testing more rigorously and putting more resources into .” —Peter Attia The post #386 – Aging clocks—what they measure, how they work, and their clinical and real-world relev
Updated cardiovascular guidelines—statin use in patients as young as 30
Recommendations still may not be aggressive enough, but the needle is moving The post Updated cardiovascular guidelines—statin use in patients as young as 30 appeared first on Peter Attia .
Thinking in trade-offs: a necessary antidote to diet tribalism
Finding a diet that sustainably works for you is enough of a win. Why pretend it has no downsides? The post Thinking in trade-offs: a necessary antidote to diet tribalism appeared first on Peter Attia .
Protect the eyes, protect the brain—a potentially simple lever for dementia risk
Uncorrected cataracts may do more than blur your vision. A recent meta-analysis explores what restoring sight could mean for long-term dementia risk. The post Protect the eyes, protect the brain—a potentially simple lever for dementia risk appeared first on Peter Attia .
#385 – AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more
“ Everything we're doing is simultaneously geared towards reducing the risk of chronic disease but also improving healthspan ." —Peter Attia The post #385 – AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury r
When sophisticated models meet questionable premises
Mendelian randomization is a powerful tool—but not when you’re asking genes to answer the wrong question The post When sophisticated models meet questionable premises appeared first on Peter Attia .
#384 – Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer’s prevention
" It's hard for me to mask my personal optimism around this. I love the biological plausibility of this, and I think that obicetrapib has done something that it's four predecessors has failed to do ." —Peter Attia The post #384 – Special episode — Obicetrapib: The CETP inhibitor
An intriguing case of “exceptional resilience” against dementia
A 75-year-old man free of dementia despite a dominant Alzheimer’s mutation — and a possible hint for the rest of us The post An intriguing case of “exceptional resilience” against dementia appeared first on Peter Attia .
Get it weekly in your inbox
The most comprehensive weekly longevity digest. No spam. Only the best of real science.
Subscribe to newsletterComing soon. Generate your protocol with My Protocol to be the first.